Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma

Documenti analoghi

• Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma
  di: Roberta Della Pepa, et al.
  Pubblicazione: (2025)
• Vaccination Uptake in Adults Post‐Haematopoietic Stem Cell Transplantation for B‐Cell Malignancies
  di: Aashir Akram, et al.
  Pubblicazione: (2026)
• Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis
  di: T. Richardson, et al.
  Pubblicazione: (2024)
• Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients
  di: Tim Strüßmann, et al.
  Pubblicazione: (2024)
• Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy
  di: Chris Armstrong, et al.
  Pubblicazione: (2025)